Literature DB >> 10910931

Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation.

B N Setty1, S Kulkarni, A K Rao, M J Stuart.   

Abstract

In sickle cell disease (SCD), loss of erythrocyte membrane phospholipid asymmetry occurs with the exposure of phosphatidylserine (PS), which provides a docking site for coagulation proteins. In vivo sickling/desickling, with resulting red cell membrane changes and microvesicle formation, appears to be one of the factors responsible for PS exposure. We evaluated children with SCD homozygous for sickle hemoglobin (SS disease) and controls (n = 65) and demonstrate that high levels of fetal hemoglobin (assessed as F cells) are associated with decreased microvesicle formation, PS exposure, and thrombin generation. F cells correlated inversely with both microvesicles and PS positivity (P <.000001) in SS disease. Multiple regression analyses using various hematologic parameters as independent variables, and either microvesicles or PS positivity as the dependent variable, showed a strong relationship only with F cells. Additionally, plasma prothrombin fragment F1.2 levels (a marker for thrombin generation) correlated with both PS positivity (P <.001) and F cells (P <.01). An F-cell level of approximately 70% was associated with normal levels of prothrombin fragment F1.2 and with microvesicle formation indistinguishable from control values. We suggest that the use of such surrogate biologic markers in conjunction with F-cell numbers may provide valuable insights into the biology and consequences of in vivo sickling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910931

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin.

Authors:  Anna Falanga; Alice Trinchero
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

Review 2.  Hypercoagulability and thrombotic complications in hemolytic anemias.

Authors:  Kenneth I Ataga
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Authors:  Stéphane M Camus; João A De Moraes; Philippe Bonnin; Paul Abbyad; Sylvain Le Jeune; François Lionnet; Laurent Loufrani; Linda Grimaud; Jean-Christophe Lambry; Dominique Charue; Laurent Kiger; Jean-Marie Renard; Claire Larroque; Hervé Le Clésiau; Alain Tedgui; Patrick Bruneval; Christina Barja-Fidalgo; Antigoni Alexandrou; Pierre-Louis Tharaux; Chantal M Boulanger; Olivier P Blanc-Brude
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

4.  Laboratory tests for coagulation system monitoring in a patient with β-thalassemia.

Authors:  Elena A Seregina; Olga F Nikulina; Nina V Tsvetaeva; Maya N Rodionova; Irina V Gribkova; Elena B Orel; Anastasiya P Zapariy; Anatoliy V Erasov; Anna N Balandina; Natalya M Ananyeva; Fazoil I Ataullakhanov
Journal:  Int J Hematol       Date:  2014-03-09       Impact factor: 2.490

5.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 6.  The Role of Circulating Cell-Free Hemoglobin in Sepsis-Associated Acute Kidney Injury.

Authors:  V Eric Kerchberger; Lorraine B Ware
Journal:  Semin Nephrol       Date:  2020-03       Impact factor: 5.299

7.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

Review 8.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 9.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

10.  Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children.

Authors:  Danitza Nébor; Marc Romana; Raoul Santiago; Nathalie Vachiery; Julien Picot; Cédric Broquere; Vicky Chaar; Lydia Doumdo; Marie-Hélène Odièvre; Malika Benkerrou; Jacques Elion
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.